Gilles Martin

Gilles Martin founded Eurofins Scientific in 1987 as a small French analytical testing laboratory and built it over nearly four decades into the world's largest network of testing laboratories. Through a relentless acquisition strategy — over 500 deals and counting — Eurofins expanded into food testing, pharmaceutical testing, environmental testing, clinical diagnostics, and genomic services across more than 60 countries. Martin's growth model is distinctive: he identifies fragmented testing markets, acquires small and mid-size laboratories at reasonable valuations, integrates them into Eurofins' global network to achieve scale advantages in procurement and operations, and cross-sells services across the combined platform. This "acquisition machine" model delivered consistent double-digit revenue growth for decades. COVID-19 testing provided an extraordinary windfall — Eurofins generated billions in COVID PCR testing revenue that funded further expansion. The post-COVID normalization has been Martin's key challenge: as COVID testing revenue evaporated, Eurofins needed to demonstrate that its organic base business could sustain the growth trajectory and justify the elevated cost base built during the pandemic. Martin's decisions on acquisition pace, organic growth investment, margin improvement programs, and capital allocation between deals and deleveraging are the primary stock drivers. Governance has also been scrutinized — as founder, chairman, and CEO with a controlling stake, Martin operates with minimal board oversight.